Raras
Buscar doenças, sintomas, genes...
Doença de Alzheimer de início precoce autossômica dominante
ORPHA:1020CID-10 · G30.0CID-11 · 6D80.0DOENÇA RARA

Uma demência progressiva com redução das funções cognitivas. Apresenta o mesmo fenótipo da doença de Alzheimer (DA) esporádica, mas tem início precoce, geralmente antes dos 60 anos.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Uma demência progressiva com redução das funções cognitivas. Apresenta o mesmo fenótipo da doença de Alzheimer (DA) esporádica, mas tem início precoce, geralmente antes dos 60 anos.

Pesquisas ativas
2 ensaios
5 total registrados no ClinicalTrials.gov
Publicações científicas
6 artigos
Último publicado: 2021 Sep 1

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
Adult
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G30.0
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
20 sintomas
💪
Músculos
2 sintomas
🦴
Ossos e articulações
2 sintomas
🛡️
Imunológico
1 sintomas
🫃
Digestivo
1 sintomas

+ 27 sintomas em outras categorias

Características mais comuns

90%prev.
Mioclonias
Muito frequente (99-80%)
90%prev.
Agitação
Muito frequente (99-80%)
90%prev.
Emaranhados neurofibrilares
Muito frequente (99-80%)
90%prev.
Confusão
Muito frequente (99-80%)
90%prev.
Parkinsonismo
Muito frequente (99-80%)
90%prev.
Hipertonia
Muito frequente (99-80%)
53sintomas
Muito frequente (15)
Frequente (1)
Ocasional (10)
Sem dados (27)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 53 características clínicas mais associadas, ordenadas por frequência.

MiocloniasMyoclonus
Muito frequente (99-80%)90%
AgitaçãoAgitation
Muito frequente (99-80%)90%
Emaranhados neurofibrilaresNeurofibrillary tangles
Muito frequente (99-80%)90%
ConfusãoConfusion
Muito frequente (99-80%)90%
ParkinsonismoParkinsonism
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa5desde 2021
Total histórico6PubMed
Últimos 10 anos1publicações
Pico20211 papers
Linha do tempo
2021Hoje · 2026🧪 2012Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

9 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant.

PSEN2Presenilin-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein) (PubMed:10497236, PubMed:10652302, PubMed:16752394, PubMed:27293189, PubMed:36272978). Selectively cleaves late endosomal/lysosomal localized substrates and generates the prominent pool of intracellular amyloid beta that contains longer amyloid beta (PubMed:27293189). The holoprotein func

LOCALIZAÇÃO

Endoplasmic reticulum membraneGolgi apparatus membraneLate endosome membraneLysosome membrane

VIAS BIOLÓGICAS (10)
Activated NOTCH1 Transmits Signal to the NucleusNOTCH3 Activation and Transmission of Signal to the NucleusNOTCH4 Activation and Transmission of Signal to the NucleusNoncanonical activation of NOTCH3NOTCH2 Activation and Transmission of Signal to the Nucleus
MECANISMO DE DOENÇA

Alzheimer disease 4

A familial early-onset form of Alzheimer disease. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
24.2 TPM
Pituitária
23.2 TPM
Cerebelo
22.9 TPM
Esôfago - Muscular
22.6 TPM
Testículo
22.2 TPM
OUTRAS DOENÇAS (4)
dilated cardiomyopathy 1VAlzheimer disease 4familial isolated dilated cardiomyopathyearly-onset autosomal dominant Alzheimer disease
HGNC:9509UniProt:P49810
PLAUUrokinase-type plasminogen activatorCandidate gene tested inTolerante
FUNÇÃO

Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (1)
Neutrophil degranulation
MECANISMO DE DOENÇA

Quebec platelet disorder

An autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.

EXPRESSÃO TECIDUAL(Ubíquo)
Rim - Medula
117.9 TPM
Baço
67.0 TPM
Adipose Visceral Omentum
64.7 TPM
Pulmão
38.4 TPM
Tecido adiposo
36.8 TPM
OUTRAS DOENÇAS (2)
Quebec platelet disorderAlzheimer disease type 1
HGNC:9052UniProt:P00749
APOEApolipoprotein ECandidate gene tested inTolerante
FUNÇÃO

APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids (PubMed:14754908, PubMed:1911868, PubMed:6860692). APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance (PubMed:14754908, PubMed:1911868, PubMed:1917954, PubMed:23620513, PubMed:2762297, PubMed:6860692, PubMed:9395455). Apolipoproteins are amphipathic mole

LOCALIZAÇÃO

SecretedSecreted, extracellular spaceSecreted, extracellular space, extracellular matrixExtracellular vesicleEndosome, multivesicular body

VIAS BIOLÓGICAS (9)
Nuclear signaling by ERBB4Scavenging by Class A ReceptorsTranscriptional regulation by the AP-2 (TFAP2) family of transcription factorsChylomicron assemblyHDL remodeling
MECANISMO DE DOENÇA

Hyperlipoproteinemia 3

A disorder characterized by the accumulation of intermediate-density lipoprotein particles (IDL or broad-beta-lipoprotein) rich in cholesterol. Clinical features include xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause.

OUTRAS DOENÇAS (6)
lipoprotein glomerulopathyhyperlipoproteinemia type 3sea-blue histiocyte syndromeAlzheimer disease 2
HGNC:613UniProt:P02649
MPOMyeloperoxidaseCandidate gene tested inTolerante
FUNÇÃO

Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity (PubMed:9922160). Mediates the proteolytic cleavage of alpha-1-microglobulin to form t-alpha-1-microglobulin, which potently inhibits oxidation of low-

LOCALIZAÇÃO

Lysosome

VIAS BIOLÓGICAS (1)
Neutrophil degranulation
MECANISMO DE DOENÇA

Myeloperoxidase deficiency

A disorder characterized by decreased myeloperoxidase activity in neutrophils and monocytes that results in disseminated candidiasis.

EXPRESSÃO TECIDUAL(Tecido-específico)
Sangue
21.3 TPM
Baço
13.2 TPM
Pulmão
6.6 TPM
Pituitária
2.6 TPM
Glândula salivar
2.1 TPM
OUTRAS DOENÇAS (2)
myeloperoxidase deficiencyAlzheimer disease type 1
HGNC:7218UniProt:P05164
TREM2Triggering receptor expressed on myeloid cells 2Candidate gene tested inTolerante
FUNÇÃO

Forms a receptor signaling complex with TYROBP which mediates signaling and cell activation following ligand binding (PubMed:10799849). Acts as a receptor for amyloid-beta protein 42, a cleavage product of the amyloid-beta precursor protein APP, and mediates its uptake and degradation by microglia (PubMed:27477018, PubMed:29518356). Binding to amyloid-beta 42 mediates microglial activation, proliferation, migration, apoptosis and expression of pro-inflammatory cytokines, such as IL6R and CCL3, a

LOCALIZAÇÃO

Cell membraneSecreted

VIAS BIOLÓGICAS (4)
DAP12 signalingDAP12 interactionsOther semaphorin interactionsImmunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
MECANISMO DE DOENÇA

Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2

An autosomal recessive disease characterized by presenile frontal dementia with leukoencephalopathy and basal ganglia calcification. In most cases the disorder first manifests in early adulthood as pain and swelling in ankles and feet, followed by bone fractures. Neurologic symptoms manifest in the fourth decade of life as a frontal lobe syndrome with loss of judgment, euphoria, and disinhibition. Progressive decline in other cognitive domains begins to develop at about the same time. The disorder culminates in a profound dementia and death by age 50 years.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
47.7 TPM
Substância negra
20.1 TPM
Pulmão
17.4 TPM
Nervo tibial
14.5 TPM
Hipotálamo
10.7 TPM
OUTRAS DOENÇAS (8)
polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2amyotrophic lateral sclerosisprogressive non-fluent aphasiabehavioral variant of frontotemporal dementia
HGNC:17761UniProt:Q9NZC2
SORL1Sortilin-related receptorDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Sorting receptor that directs several proteins to their correct location within the cell (Probable). Along with AP-1 complex, involved Golgi apparatus - endosome sorting (PubMed:17646382). Sorting receptor for APP, regulating its intracellular trafficking and processing into amyloidogenic-beta peptides. Retains APP in the trans-Golgi network, hence preventing its transit through late endosomes where amyloid beta peptides Abeta40 and Abeta42 are generated (PubMed:16174740, PubMed:16407538, PubMed

LOCALIZAÇÃO

Golgi apparatus membraneGolgi apparatus, trans-Golgi network membraneEndosome membraneEarly endosome membraneRecycling endosome membraneEndoplasmic reticulum membraneEndosome, multivesicular body membraneCell membraneCytoplasmic vesicle, secretory vesicle membraneSecreted

VIAS BIOLÓGICAS (1)
Amyloid fiber formation
MECANISMO DE DOENÇA

Alzheimer disease

Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
103.0 TPM
Linfócitos
94.0 TPM
Cérebro - Hemisfério cerebelar
54.1 TPM
Cerebelo
53.9 TPM
Brain Frontal Cortex BA9
37.7 TPM
OUTRAS DOENÇAS (1)
early-onset autosomal dominant Alzheimer disease
HGNC:11185UniProt:Q92673
TOMM40Mitochondrial import receptor subunit TOM40 homologBiomarker tested inAltamente restrito
FUNÇÃO

Channel-forming protein that forms part of the translocase of the outer mitochondrial membrane (TOM) complex essential for the recognition and translocation of cytosolically synthesized mitochondrial preproteins (PubMed:15644312, PubMed:31206022, PubMed:40080546). The TOM complex associates with the ion channel VDAC2 and PINK1 kinase at depolarized mitochondria, this interaction stabilizes PINK1 at the outer mitochondrial membrane and triggers downstream mitophagy by the recruitment of the E3 ub

LOCALIZAÇÃO

Mitochondrion outer membrane

VIAS BIOLÓGICAS (2)
PINK1-PRKN Mediated MitophagyMitochondrial protein import
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
59.7 TPM
Cérebro - Hemisfério cerebelar
39.4 TPM
Fibroblastos
38.4 TPM
Esôfago - Mucosa
37.8 TPM
Cerebelo
37.5 TPM
OUTRAS DOENÇAS (1)
early-onset autosomal dominant Alzheimer disease
HGNC:18001UniProt:O96008
PSEN1Presenilin-1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalytic subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein) (PubMed:10206644, PubMed:10545183, PubMed:10593990, PubMed:10811883, PubMed:10899933, PubMed:12679784, PubMed:12740439, PubMed:15274632, PubMed:20460383, PubMed:25043039, PubMed:26280335, PubMed:28269784, PubMed:30598546, PubMed:30630874). Requires the presence of the other members of the

LOCALIZAÇÃO

Endoplasmic reticulumEndoplasmic reticulum membraneGolgi apparatus membraneCytoplasmic granuleCell membraneCell projection, growth coneEarly endosomeEarly endosome membraneCell projection, neuron projectionCell projection, axonSynapse

VIAS BIOLÓGICAS (1)
Neutrophil degranulation
MECANISMO DE DOENÇA

Alzheimer disease 3

A familial early-onset form of Alzheimer disease. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
39.3 TPM
Skin Sun Exposed Lower leg
25.1 TPM
Skin Not Sun Exposed Suprapubic
22.8 TPM
Nervo tibial
20.5 TPM
Fibroblastos
19.7 TPM
OUTRAS DOENÇAS (9)
semantic dementiaPick diseaseAlzheimer disease 3acne inversa, familial, 3
HGNC:9508UniProt:P49768
APPAmyloid-beta precursor proteinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis (PubMed:25122912). Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptos

LOCALIZAÇÃO

Cell membraneMembranePerikaryonCell projection, growth coneMembrane, clathrin-coated pitEarly endosomeCytoplasmic vesicleEndoplasmic reticulumGolgi apparatusSecretedCell surfaceNucleusCytoplasm

VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
MECANISMO DE DOENÇA

Alzheimer disease 1

A form of Alzheimer disease, a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death. It can be associated with cerebral amyloid angiopathy. Alzheimer disease can be associated with cerebral amyloid angiopathy.

OUTRAS DOENÇAS (9)
cerebral amyloid angiopathy, APP-relatedAlzheimer disease type 1ABeta amyloidosis, Italian typeearly-onset autosomal dominant Alzheimer disease
HGNC:620UniProt:P05067

Variantes genéticas (ClinVar)

161 variantes patogênicas registradas no ClinVar.

🧬 PSEN2: NM_000447.3(PSEN2):c.-21+2dup ()
🧬 PSEN2: NM_000447.3(PSEN2):c.524C>T (p.Ser175Phe) ()
🧬 PSEN2: NM_000447.3(PSEN2):c.356+2T>C ()
🧬 PSEN2: GRCh37/hg19 1q21.1-44(chr1:143932350-249224684)x3 ()
🧬 PSEN2: NM_000447.3(PSEN2):c.1266C>G (p.Phe422Leu) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 2 variantes classificadas pelo ClinVar.

2
Patogênica (100.0%)
VARIANTES MAIS SIGNIFICATIVAS
PSEN1: NM_000021.4(PSEN1):c.854C>T (p.Ala285Val) [Pathogenic]
PSEN1: NM_000021.4(PSEN1):c.856C>G (p.Leu286Val) [Pathogenic]

Vias biológicas (Reactome)

47 vias biológicas associadas aos genes desta condição.

Nuclear signaling by ERBB4 Regulated proteolysis of p75NTR NRIF signals cell death from the nucleus Activated NOTCH1 Transmits Signal to the Nucleus Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants NOTCH2 Activation and Transmission of Signal to the Nucleus EPH-ephrin mediated repulsion of cells NOTCH3 Activation and Transmission of Signal to the Nucleus NOTCH4 Activation and Transmission of Signal to the Nucleus Noncanonical activation of NOTCH3 TGFBR3 PTM regulation Neutrophil degranulation Dissolution of Fibrin Clot Scavenging by Class A Receptors Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors Post-translational protein phosphorylation Chylomicron assembly Chylomicron remodeling Chylomicron clearance HDL remodeling NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux Retinoid metabolism and transport Amyloid fiber formation Events associated with phagocytolytic activity of PMN cells Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell DAP12 interactions DAP12 signaling Other semaphorin interactions Mitochondrial protein import PINK1-PRKN Mediated Mitophagy Degradation of the extracellular matrix Platelet degranulation ECM proteoglycans G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Mitochondrial protein degradation

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
1Fase 11
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 2 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença de Alzheimer de início precoce autossômica dominante

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
1 papers (10 anos)

Publicações recentes

Ver todas no PubMed

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença de Alzheimer de início precoce autossômica dominante.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença de Alzheimer de início precoce autossômica dominante

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Multimodal Imaging in a Patient With Alzheimer Disease and Parkinsonism Because of a Presenilin-1 Mutation.
    Clinical nuclear medicine· 2021· PMID 33883498mais citado
  2. Impact of gene patents and licensing practices on access to genetic testing for Alzheimer disease.
    Genet Med· 2010· PMID 20393312recente
  3. Novel insertional presenilin 1 mutation causing Alzheimer disease with spastic paraparesis.
    Neurology· 2004· PMID 15159497recente
  4. Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations.
    Am J Geriatr Psychiatry· 2004· PMID 15010344recente
  5. A novel mutation in the PSEN2 gene (T430M) associated with variable expression in a family with early-onset Alzheimer disease.
    Arch Neurol· 2003· PMID 12925374recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:1020(Orphanet)
  2. MONDO:0015140(MONDO)
  3. GARD:12798(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55345929(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença de Alzheimer de início precoce autossômica dominante
Compêndio · Raras BR

Doença de Alzheimer de início precoce autossômica dominante

ORPHA:1020 · MONDO:0015140
Prevalência
1-9 / 100 000
Herança
Autosomal dominant
CID-10
G30.0 · Doença de Alzheimer de início precoce
CID-11
Ensaios
2 ativos
Início
Adult
Prevalência
0.0 (Europe)
MedGen
UMLS
C0276496
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades